SavedAdd your journal

Journals / Acta Medica / 2022 / Cilt: 53 - Sayı: 3

The Effect of Statin Use on In-Hospital Mortality in Covid-19 Patients

Abdurrahman AKYÜZ
Burhan ASLAN
Ferhat IŞIK
Murat ÇAP
İlyas KAYA
Özgür ATLI
Ümit İNCİ
Ercan TAŞTAN
Önder BİLGE
Metin OKŞUL
Mehmet Zülküf KARAHAN
Pages
219–226
Publication Date
2022-11-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to this model; increased age (odds ratio (OR) =1.051, 95% confidence interval (CI) 1.039-1.063, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Our aim in this study was to determine whether statins with anti-inflammatory and antithrombotic properties reduce in-hospital mortality in Covid-19 patients.
📊
Key Findings & Data:Materials and Methods: 1752 patients hospitalized with the diagnosis of Covid-19 between September and December 2020 were retrospectively analyzed.
💡
Conclusion & Impact:According to this model; increased age (odds ratio (OR) =1.051, 95% confidence interval (CI) 1.039-1.063, p
🔬Design:Modeling & Simulation
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Our aim in this study was to determine whether statins with anti-inflammatory and antithrombotic properties reduce in-hospital mortality in Covid-19 patients. Materials and Methods: 1752 patients hospitalized with the diagnosis of Covid-19 between September and December 2020 were retrospectively analyzed. The patients were grouped according to statin use and their characteristics were compared. The parameters associated with mortality were examined. Results: For the patients, the median age was 64 years (53-74 interquartile range [IQR]), 804 (45.9%) were over the age of 65, 903 (51.5%) were male, 167 (9.5%) were using statins, and mortality developed in 381 (21.7%) of the patients. The multivariate logistic regression model was applied using statistically significant parameters in the univariate analysis of mortality development. The group using statins was included in the regression model because it was statistically borderline significant (p=0.052). According to this model; increased age (odds ratio (OR) =1.051, 95% confidence interval (CI) 1.039-1.063, p

🔖

Cite This Article

AKYÜZ, A., ASLAN, B., IŞIK, F., ÇAP, M., KAYA, İ., ATLI, Ö., İNCİ, Ü., TAŞTAN, E., BİLGE, Ö., OKŞUL, M., KARAHAN, M. Z. (2022). The Effect of Statin Use on In-Hospital Mortality in Covid-19 Patients. Acta Medica, Cilt: 53 - Sayı: 3, 219–226. https://ajindex.com/articles/655771

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ. 2020;368:m1036
  2. Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020;14:1149–63. https://doi.org/1 0.1080/17476348.2020.1804365 [3] Malas MB, Naazie IN, Elsayed N, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and metaanalysis. EClinicalMedicine. 2020;29–30:100639. https://doi. org/10.1016/j.eclinm.2020.100639 [4] Hojyo S, Uchida M, Tanaka K, et al. How COVID-19 induces cytokine storm with high mortality. Infamm Regen. 2020;40:37. https://doi. org/10.1186%2Fs41232-020-00146-3 [5] Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med. 2020;1:1–4.
  3. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–8. https://doi.org/10.1016/S0140- 6736(20)30937-5 [7] Abou-Ismail MY, Diamond A, Kapoor S, et al. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101–15. https://doi.org/10.1016/j. thromres.2020.06.029 [8] Radenkovic D, Chawla S, Pirro M, et al. Cholesterol in relation to COVID-19: should we care about it? J Clin Med. 2020;9:1909.
  4. Castiglione V, Chiriacò M, Emdin M, et al. Statin therapy in COVID-19 infection. Eur Hear J Cardiovasc Pharmacother. 2020.
  5. Lee KCH, Sewa DW, Phua GC. Potential role of statins in COVID19. Int J Infect Dis. 2020;96:615–7. https://doi. org/10.1016/j.ijid.2020.05.115 [11] Fedson DS. Treating infuenza with statins and other immunomodulatory agents. Antiviral Res. 2013;99:417– 35.
  6. Grudzinska FS, Dosanjh DP, Parekh D, et al. Statin therapy in patients with community-acquired pneumonia. Clin Med (Northfeld Il). 2017;17:403–7. https://doi.org/10.7861/ clinmedicine.17-5-403 [13] Cariou B, Goronfot T, Rimbert A, et al. Routine use of statins and increased mortality related to COVID-19 in inpatients with type 2 diabetes: Results from the CORONADO study. Diabetes Metab. 2020. https://doi.org/10.1016/j. diabet.2020.10.001 [14]